FSL0580

Structure

• InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)
• InChIKey=HEMJJKBWTPKOJG-UHFFFAOYSA-N

Synonyms

• 25812-30-0
• Gemfibrozil

Origin

Chemically synthesized

Biological activities

PPAR activation (up-regulation of tripeptidyl-peptidase)

Therapeutic

Hyperlipidemia
(lipid-lowering drug)

Target

Peroxisome proliferator-activated receptor α (PPARα)

Assay information

Up-regulates tripeptidylpeptidase 1 in brain cells via PPARα (effective dose: ca 10 μM)
Increases myelin genes in human oligodendrocytes via PPARβ (effective dose: ca 10 μM)

References

• Ghosh A, Corbett GT, Gonzalez FJ, Pahan K
  Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor ?: implications for late infantile Batten disease therapy.
  J Biol Chem, 287(46): 38922-38935 (2012)  22989886  doi: 10.1074/jbc.M112.365148
• Jana M, Mondal S, Gonzalez FJ, Pahan K
  Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-?.
  J Biol Chem, 287(41): 34134-34148 (2012)  22879602  doi: 10.1074/jbc.M112.398552
• de Salcedo I, Gorringe AL, Silva JL, Santos JA
  Gemfibrozil in a group of diabetics.
  Proc R Soc Med, 69 Suppl 2: 64-70 (1976)  1019155
• Nikkilä EA, Ylikahri R, Huttunen JK
  Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.
  Proc R Soc Med, 69 Suppl 2: 58-63 (1976)  190608